BGI Genomics not too long ago participated in a mission enterprise to South America in April 2023. Provided that this continent ranks fourth in space and fifth in inhabitants worldwide, the financial and healthcare enhancement potential of this continent is compelling.
Picture Credit score: BGI Genomics
Each South American nation faces completely different healthcare challenges and priorities. Nonetheless, the promise of precision medication is obvious: It provides a chance to shift the supply of care from a legacy one-size-fits-all strategy to making use of the suitable therapy for the suitable affected person on the proper time.
To assist ship on precision medication’s potential, BGI Genomics considers genetic testing to be pivotal to the medical screening, prognosis and therapy of ailments. As a number one built-in options supplier of precision medication, the corporate appears ahead to long-term cooperation with main native companions to additional improve well being outcomes.
On the China-Brazil Financial and Commerce Cooperation Convention within the metropolis of Sao Paulo, BGI Genomics and , a frontrunner in medical testing within the nation, signed a cooperation settlement on April 17, agreeing to long-term cooperation in medical medical testing and introducing the corporate’s services and products to the Brazilian market, equivalent to prenatal screening and most cancers tumor screening.
Subsequently, on April 17, the corporate signed a considerable order with , a number one precision medication service supplier in Argentina, which plans to buy a large-scale high-throughput sequencing platform system and associated automation tools for native scientific analysis and improve medical providers.
BGI Genomics has additionally reached a cooperation settlement with diagnostic service provider will present an entire set of non-invasive prenatal genetic testing tools and options to this Buenos Aires-based firm. With this partnership, testing is finished domestically as an alternative of sending samples to abroad laboratories, thus lowering the fee for native pregnant ladies and serving to Argentina enhance maternal well being providers.
The Precision Oncology Middle of , a number one Chilean college, additionally obtained two cutting-edge sequencers and different tools from BGI Genomics. This partnership will assist launch Chile’s most intensive most cancers genomics laboratory. The signing ceremony of this settlement was held on April 18, attended by the Vice Chancellor of Analysis, Nicole Trefault, and the overall supervisor for Latin America, BGI Genomics, Liang Wu.
“The Precision Oncology Middle places medication on the service of the folks in an unprecedented effort to maneuver in direction of democratizing entry to frontier medical remedies within the space of most cancers, the main explanation for dying in our nation. We now can depend on an important sequencing laboratory in Chile with tools that permits evaluation to be carried out in better depth, in much less time, and at a decrease value.”
Dr. Patricio Manque
Liang Wu notes that the corporate seeks to profit the native inhabitants by elevating technological well being requirements, “Over the previous few years, we’ve launched into a collection of collaborative tasks in Latin America, yielding exceptional outcomes. Our collaborations embody establishing laboratories, offering technical assist, and implementing coaching applications.”
About BGI Genomics
, headquartered in Shenzhen, China, is the world’s main built-in options supplier of precision medication. Our providers cowl over 100 international locations and areas, involving greater than 2,300 medical establishments. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was formally listed on the Shenzhen Inventory Alternate.